On this page

Ketoconazole

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Ketoconazole
Generic name
Ketoconazole
Dosage form
Shampoo
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Zydus Lifesciences Limited
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
3
Packages
3
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Ketoconazole 20 mg/mL 197853 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Shampoo
Route of administration
Topical
Presentations
6

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Azole Antifungal [EPC] EPC All 44 members
Azoles [CS] CS All 44 members
Cytochrome P450 3A4 Inhibitors [MoA] MoA All 118 members
Cytochrome P450 3A5 Inhibitors [MoA] MoA 7 members — no class page
P-Glycoprotein Inhibitors [MoA] MoA All 105 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
218559
Application type
ANDA · Abbreviated New Drug Application
Approval date
March 7, 2025
Sponsor
ZYDUS LIFESCIENCES
Products on application
1
Submissions recorded
1
Products approved under application 218559.
Product Trade name Form Strength Ingredient Status TE Flags
218559-001 KETOCONAZOLE SHAMPOO KETOCONAZOLE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 218559.
Type No. Action Status Date Review
Original application 1 Approved March 7, 2025 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260129). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260129 HUMAN PRESCRIPTION DRUG · 20240311

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Ketoconazole shampoo, 2% is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by Pityrosporum orbiculare (also known as Malassezia furfur or M. orbiculare ). Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in normalization of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. Although tinea versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply the shampoo to the damp skin of the affected area and a wide margin surrounding this area. Lather, leave in place for 5 minutes and then rinse off with water. One application of the shampoo should be sufficient.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Ketoconazole shampoo, 2% is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Clinical Trials Experience In 11 double-blind trials in 264 patients using ketoconazole shampoo, 2% for the treatment of dandruff or seborrheic dermatitis, an increase in normal hair loss and irritation occurred in less than 1% of patients. In three open-label safety trials in which 41 patients shampooed 4 times to 10 times weekly for six months, the following adverse experiences each occurred once: abnormal hair texture, scalp pustules, mild dryness of the skin and itching. As with other shampoos, oiliness and dryness of hair and scalp have been reported. In a double-blind, placebo-controlled trial in which patients with tinea versicolor were treated with either a single application of ketoconazole shampoo, 2% (n=106), a daily application for three consecutive days (n=107) or placebo (n=105), drug-related adverse events occurred in 5 (5%), 7 (7%) and 4 (4%) of patients, respectively. The only events that occurred in more than one patient in any one of the three treatment groups were pruritus, application site reaction and dry skin; none of these events occurred in more than 3% of the patients in any one of the three groups. Post-marketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. The following adverse drug reactions have been identified during post-marketing experience with ketoconazole shampoo, 2%: there have been reports of hair discoloration and abnormal hair texture, itching, skin burning sensation, contact dermatitis, hypersensitivity, angioedema, alopecia, rash, urticaria, skin irritation, dry skin and application site reactions. To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION For Topical Application Only Ketoconazole shampoo, 2% is a red-orange liquid for topical application, containing the broad spectrum synthetic antifungal agent ketoconazole in a concentration of 2% in an aqueous suspension. It also contains: cocodiethanolamide, disodium laureth sulfosuccinate, FD&C red no. 40, hydrochloric acid, imidurea, laurdimonium hydroxypropyl hydrolyzed animal collagen, PEG-120 methyl glucose dioleate, purified water, sodium chloride, sodium hydroxide and sodium lauryl ether sulfate. Ketoconazole is cis -1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1 H -imidazol-1- ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine and has the following structural formula: Ketoconazole shampoo-image01

OVERDOSAGE Ketoconazole shampoo, 2% is intended for external use only. In the event of accidental ingestion, supportive and symptomatic measures should be employed. Induced emesis and gastric lavage should not be performed to avoid aspiration.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Ketoconazole Shampoo, 2% is a red-orange color liquid supplied in a 4-fluid ounce (120 mL) non-breakable plastic bottle (NDC 70954-662-10). Storage conditions: Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light. All trademarks are the property of their respective owners. Distributed by: ANI Pharmaceuticals, Inc. Baudette, MN 56623 Issued: 07/2024 LB4643-01

Adverse event reports

Source: openFDA FAERS
17,282
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: KETOCONAZOLE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
70954-662-10 70954-662 ANI Pharmaceuticals, Inc. 120 mL in 1 BOTTLE, PLASTIC (70954-662-10) September 16, 2024
72578-156-12 72578-156 Viona Pharmaceuticals Inc 120 mL in 1 BOTTLE (72578-156-12) March 8, 2025
70771-1874-7 70771-1874 Zydus Lifesciences Limited 120 mL in 1 BOTTLE (70771-1874-7) March 8, 2025
70954-662 70954-662 ANI Pharmaceuticals, Inc. — September 16, 2024
72578-156 72578-156 Viona Pharmaceuticals Inc — March 8, 2025
70771-1874 70771-1874 Zydus Lifesciences Limited — March 8, 2025

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.